Compare Biogen Inc (BIIB) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Hershey Co — how do they compare? Biogen Inc trades at $197.24 (market cap $28.34B), while Hershey Co trades at $170.1 (market cap $34.78B). The key difference: Hershey Co is the larger of the two by market cap, and Hershey Co pays a 3.39% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | HSY | |
|---|---|---|
Market Cap | $28.34B | $34.78B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $236.28 |
52-Week Low | $122.68 | $162.31 |
Enterprise Value | $30.62B | $39.58B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Hershey (HSY) trades at $175.24, up 0.91% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.35 versus $2.04 expected. Revenue growth is steady, with 2025 revenue at $11.69 billion, though net income margin compressed to 9.12% from prior years. Analyst consensus price target is $209.25, implying significant upside, supported by a 3.3% dividend yield and recent margin recovery trends.
The outlook for HSY is cautiously optimistic, with earnings momentum and valuation support offset by near-term technical weakness. Investment opportunity lies in continued execution on margin improvement and innovation, such as new REESE'S PIECES products. Key risks include persistent input cost pressures, competitive threats, and macroeconomic sensitivity. Wall Street sentiment is mixed, with 65.7% hold ratings reflecting balanced risk-reward amid recovery phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
